Top 10 blockbuster Cancer Drugs of 2018
Paclitaxel was the first cancer medication to make it to cancer blockbuster drugs market with more than $1 billion in sales.
The median price of the new cancer medication crossed $150 thousand which was launched in the year 2017,
as per the recent pharmaceutical market research reports.
The median price of the new cancer medication crossed $150 thousand which was launched in the year 2017,
as per the recent pharmaceutical market research reports.
In the global oncology drug blockbuster market, the US observed a rapid increase in the spending of cancer treatments.
This is a case for more than 5 years reaching around $50 billion in the year 2017.
This is a case for more than 5 years reaching around $50 billion in the year 2017.
This accumulates to more than 50% of the total drug cost in the rest of the world which is around $60 billion.
In the Global Oncology/Cancer Blockbuster Drugs Market, the treatments launched in the last five years have brought increased revenue in the global industry.
In the Global Oncology/Cancer Blockbuster Drugs Market, the treatments launched in the last five years have brought increased revenue in the global industry.
The following are the 10 Best-Selling Cancer Drugs of 2018.
10. Xtandi® (enzalutamide)
Astellas Pharma and Pfizer - Androgen receptor inhibitor
9. Ibrance® (palbociclib)
Pfizer - Kinase inhibitor
8. Neulasta/Peglasta (pegfilgrastim)
Amgen and Kyowa Hakko Kirin -Leukocyte growth factor
7. Imbruvica® (ibrutinib)
Pharmacyclics (AbbVie) and Johnson & Johnson (J&J) -Kinase inhibitor
6. Rituxan®/MabThera (rituximab)
Genentech (Roche) and Biogen 2 - CD20-directed cytolytic antibody
5. Avastin
Roche - Vascular endothelial growth factor–directed antibody
4. Herceptin
Roche (Genentech)- Type of Drug: HER2/neu receptor antagonist
3. Keytruda
Merck & Co. - Programmed death receptor-1 (PD-1)-blocking antibody
2. Opdivo
Bristol-Myers Squibb (BMS) and Ono Pharmaceutical - Programmed death receptor-1 (PD-1) blocking antibody
1. Revlimid - Celgene- Thalidomide analog
As per pharmaceutical industry reports, the US cancer drug prices
are projected to observe another considerable increase valuing $100 billion by the year 2022. It will be interesting to see how the CAGR of the industry grows outside the US in the next five years. The upcoming market trends and development in the industry may boost the demand and growth of the global market.
are projected to observe another considerable increase valuing $100 billion by the year 2022. It will be interesting to see how the CAGR of the industry grows outside the US in the next five years. The upcoming market trends and development in the industry may boost the demand and growth of the global market.
Comments
Post a Comment